NOVELIX PHARMACEUTICALS LTD.
|
Market Cap.(`)
|
22.89 Cr.
|
P/BV
|
2.49
|
Book Value (`)
|
9.25
|
|
52 Week High/Low ( ` )
|
23/8
|
FV/ML
|
10/1
|
P/E(X)
|
143.75
|
|
Book Closure
|
27/09/2024
|
EPS (`)
|
0.16
|
Div Yield (%)
|
0.00
|
(` in Crs.)
You can view the
Consolidated
Income Statement
for the last 5 years.
| Months | 12 | 12 | 12 | 12 | 12 |
| Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR | AR | AR |
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| | | | | | |
| | | | | | |
| INCOME | | | | | |
| Revenue From Operations [Net] | 8.61 | 9.24 | 10.24 | 10.46 | 10.50 |
| Total Operating Revenues | 8.61 | 9.24 | 10.24 | 10.46 | 10.50 |
| | | | | | |
| Other Income | 0.55 | 0.34 | 0.60 | 0.38 | 0.21 |
| Total Revenue | 9.16 | 9.59 | 10.85 | 10.84 | 10.71 |
| | | | | | |
| EXPENSES | | | | | |
| Cost Of Materials Consumed | 7.44 | 2.02 | 2.12 | 1.54 | 1.16 |
| Purchase Of Stock-In Trade | 1.09 | 5.01 | 5.52 | 0.00 | 4.53 |
| Operating And Direct Expenses | 0.01 | 1.56 | 1.62 | 7.48 | 2.94 |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -0.28 | -0.03 | -0.09 | 0.02 | 0.13 |
| Employee Benefit Expenses | 0.44 | 0.99 | 0.96 | 0.99 | 0.99 |
| Finance Costs | 0.00 | 0.06 | 0.11 | 0.13 | 0.16 |
| Depreciation And Amortisation Expenses | 0.10 | 0.21 | 0.19 | 0.21 | 0.24 |
| Other Expenses | 2.49 | 3.49 | 0.62 | 0.59 | 0.77 |
| Total Expenses | 11.28 | 13.31 | 11.06 | 10.96 | 10.91 |
| | | | | | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -2.12 | -3.73 | -0.21 | -0.12 | -0.20 |
| | | | | | |
| Profit/Loss Before Tax | -2.12 | -3.73 | -0.21 | -0.12 | -0.20 |
| | | | | | |
| Tax Expenses-Continued Operations | | | | | |
| Current Tax | 0.00 | 0.00 | 0.03 | 0.11 | 0.13 |
| Deferred Tax | -0.01 | 0.01 | 0.02 | -0.08 | 0.01 |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Tax Expenses | -0.01 | 0.01 | 0.04 | 0.02 | 0.15 |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -2.11 | -3.74 | -0.26 | -0.15 | -0.35 |
| | | | | | |
| Profit/Loss From Continuing Operations | -2.11 | -3.74 | -0.26 | -0.15 | -0.35 |
| | | | | | |
| Profit/Loss For The Period | -2.11 | -3.74 | -0.26 | -0.15 | -0.35 |
| | | | | | |
| Minority Interest | 0.23 | 0.02 | -0.02 | -0.09 | -0.04 |
| Share Of Profit/Loss Of Associates | 0.09 | -0.02 | 0.00 | 0.00 | 0.00 |
| Consolidated Profit/Loss After MI And Associates | -1.80 | -3.74 | -0.28 | -0.24 | -0.39 |
| | | | | | |
| OTHER INFORMATION | | | | | |
| | | | | | |
| EARNINGS PER SHARE | | | | | |
| Basic EPS (Rs.) | -2.22 | -4.62 | -0.35 | -0.30 | -0.48 |
| Diluted EPS (Rs.) | -2.22 | -4.62 | -0.35 | -0.30 | -0.48 |